Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 2/20 | 0.39 |
| ▸ | SPNS2 | Q8IVW8 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934202 | 0.87 | HCAR2 (0.43) | TLR8HCAR3HCAR2CYP1A2CYP2C19 | |
| SCHEMBL4932341 | 0.81 | KDM4E (0.48) | CNR1GAA | |
| SCHEMBL245726 | 0.74 | TLR8 (0.49) | TLR8SPNS2 | |
| SCHEMBL15474118 | 0.69 | LMNA (0.38) | TLR8 | |
| SCHEMBL3868934 | 0.69 | SPNS2 (0.49) | TLR8SPNS2MEN1KMT2ATDP1 | |
| SCHEMBL3282934 | 0.69 | TLR8 (0.36) | TLR8CNR1 | |
| SCHEMBL6071069 | 0.69 | TLR8 (0.50) | TLR8CNR1ICMTCYP1A2CYP2C19 | |
| SCHEMBL9090191 | 0.68 | FAAH (0.39) | CNR1CYP1A2CYP2C19GAAMEN1 | |
| SCHEMBL10530730 | 0.68 | SPNS2 (0.48) | TLR8SPNS2MEN1KMT2A | |
| SCHEMBL3219891 | 0.68 | CNR1 (0.48) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799804-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| WO-2009004380-A1 | METHOD AND USE OF CIRCULATING LEVELS OF ENDOCANNABINOID LIGANDS FOR THE DETERMINATION OF PATIENT IN NEED AND/OR SUITABLE FOR CB1R ANTAGONIST DRUG TREATMENT AS WELL AS METHOD FOR INDUCING WEIGHT LOSS/MAINTENANCE/GAIN | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| CN-101263122-A | 1, 2-diarylimidazoles useful as CB1 modulators | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | CN | disclosed |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008096151-A1 | PHARMACEUTICAL COMPOSITIONS OF CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1940820-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940803-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1833802-A2 | 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070208059-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031721-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031720-A1 | 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| EP-1735287-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006067428-A2 | 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005095354-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306115-A1 | Midazole-4-Carboxamide Derivatives For Use As Cb1 Modulators | CNR2, CNR1, FAAH | TLR8 1479/4885CNR1 2/4885ICMT 4363/4885 |
| US-20090005415-A1 | 1,2-Diarylimidazoles for Use as Cb1 Modulators | CNR2, CNR1, FAAH | TLR8 1504/4885CNR1 2/4885ICMT 3951/4885 |
| US-20070208059-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | TLR8 3155/4885CNR1 193/4885ICMT 4343/4885 |
| US-20080319019-A1 | Therapeutic Agents | SDHA, GPR119, ABAT | TLR8 2042/4885CNR1 393/4885ICMT 3310/4885 |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | CNR1, CNR2, GPR18 | TLR8 3082/4885CNR1 1/4885ICMT 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.